EnlitenAI

Built an AI platform for personalizing the treatment of seizures/Epilepsy using wearables for continuous monitoring of neurological indicators.

Our platform offers data monetization opportunities.

1. Product readiness: Clinical Study at UCHealth (Colorado) completed and is a strong validation of our product.
2. Commercialization: Starts in Q3 2024
3. Strong market traction with
A. Neurology Centers: UCSF, UCHealth, Baylor, Univ of New Mexico
B. Devices - Apple, Emotiv, Neureka & Dreem3
D. EEG Annotation partner - TALOS
E. Endorsement by Epilepsy Foundation & invitation to be on their dtRRE panel
4. Reimbursement Strategy guidance created
5. Phased approach to FDA Regulatory Strategy (Class I in Q2'24 and Class II in Q4'24) - Software Assisted Medical Device

Neurologists are unable to build personalized treatment plans owing to the unpredictable nature of seizures and the lack of insights on patient specific responses to medications.  Drug titration is trial-and-error based and extremely long.  This leads to the skyrocketing cost burden for insurance carriers.  Today, wearable OEMs are able to detect seizures, but unable to synthesize real world evidence and optimize the treatment regimen is unaddressed today. They fall short.

EnlitenAI is addressing the unmet needs in personalizing the management of seizures, especially drug titration.

Neuroliten is an AI based SaaS platform that has 3ponents -
1. Digital Seizure Diary - real world evidence
2. Data Ingestion Layer - captures ambulatory EEG data (using wearables) to detect brain signal abnormalities and Vitals (using smartwatch)
3. AI Engine - builds correlation and predictive models and insights needed to personalize treatment plans. Detects Tachyphylaxis, Guides Treatment aggressiveness and Drug titration to predict which medication has the highest rate of success for a patient given his/her co-medications, comorbidities, side effects & genetic predisposition.

Our commercialization strategy is based on a SaaS monetization model. Our Go-to-market strategy is B2B, wherein each neurology center is treated as a named account. The Neurologists advocate the use of our platform by prescribing Neuroliten to the patients.

The Neurology centers get reimbursed using Remote Therapeutic Monitoring codes, that already exist, by the Payers. Their incentive is to expand their practice, more frequent billing & see more patients for better health outcomes.

Neurology centers have an incentive to work with us they generate a new stream of revenue.

Epilepsy Foundation/Danny Did Foundation Accelerator
IIT Startups
LifeX-Jumpstart Ventures
Innosphere Ventures
Aurelia Ventures